This website is now the new JPND's archival platform. This website hosts all of JPND's archived content and resources.
Please continue to visit this site to access publications, videos and reports from JPND's activities.
Title of project or programme
| Title of PI | New Metal-Protein Attenuating Compounds with Neurotrophic Properties as a Therapeutic Strategy in Alzheimer’s Disease |
Principal Investigators of project/programme grant
| Title | Forname | Surname | Institution | Country |
| Dr | Adina | Michael-Titus | University of London | UK |
Address of institution of lead PI
| Institution | Queen Mary, University of London |
| Street Address | Mile End Road |
| City | London |
| Postcode | E1 4NS |
Country
- United Kingdom
Source of funding information
Total sum awarded (Euro)
554804.55
Start date of award
10-05-2010
Total duration of award in months
24
The project/programme is most relevant to
- Alzheimer’s disease and other dementias
Keywords
Research abstract in English
Alzheimer’s disease (AD) is the most common form of dementia, a devastating disease characterised by the loss of mental function. None of the drugs currently on the market affect significantly the disease. Anti-amyloid strategies are at the core of AD research, and it has been shown that Metal Protein-Attenuating Compounds (MPACs) which bind zinc and copper, reduce amyloid load and toxicity. Clinical trial results with MPACs which are quinoline compounds show excellent tolerability and improved cognition in AD patients and therefore show that MPACs are promising new AD drugs. Our project aims to further develop new substituted phosphonate MPACs, and facilitate the selection of a compound for Phase 1. Our proprietary non-quinoline MPAC compounds have additional and unique neurotrophic properties, which are particularly relevant in the context of AD, making these compounds better than the existing MPACs. The project will provide in vitro and in vivo efficacy data, safety, toxicity, metabolism and pharmacokinetic data, and thus facilitate the choice of a candidate compound for first studies in man.
Lay summary
In which category does this research fall?
- Basic research
New Metal-Protein Attenuating Compounds with Neurotrophic Properties as a Therapeutic Strategy in Alzheimer’s Disease
Investments > €500k
United Kingdom
Alzheimer’s disease & other dementias
2011